Ipsen, Sky­hawk ink deal worth up to $1.8B; He­p­i­on to wind down NASH tri­al

Plus, news about Aslan, Take­da, Astel­las, Sum­it­o­mo Mit­sui, Kynos Ther­a­peu­tics, Oculis and Vaxxin­i­ty:

Ipsen, Sky­hawk Ther­a­peu­tics pen neu­ro­log­i­cal deal: Ipsen and Sky­hawk plan to de­vel­op small mol­e­cules that can mod­u­late RNA in a deal worth up to $1.8 bil­lion. The up­front pay­ment was not dis­closed. The deal fo­cus­es on two rare neu­ro­log­i­cal dis­ease tar­gets. Sky­hawk is re­spon­si­ble for ear­ly re­search, and Ipsen is re­spon­si­ble for all de­vel­op­ment af­ter can­di­date nom­i­na­tion. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER